FrancophonIA/ELRC3.0 huggingface dataset:
English: If you think you may be allergic to any component of this medicine, talk to your doctor before taking Entresto.
Danish: Hvis du tror, at du er allergisk over for noget af indholdet i denne medicin, skal du spørge lægen til råds, før du tager Entresto.
English: In PARADIGM-HF, angioedema was reported in 0.5% of patients treated with Entresto, compared with 0.2% of patients treated with enalapril.
Danish: I PARADIGM-HF blev angioødem rapporteret hos 0,5 % af patienter behandlet med Entresto sammenlignet med 0,2 % hos patienter behandlet med enalapril.
English: In vitro metabolism studies indicate that potential for CYP 450-based drug interactions is low since there is limited metabolism of Entresto via CYP450 enzymes.
Danish: In-vitro-metaboliseringsstudier tyder på, at der kun er lille potentiale for CYP-baserede lægemiddelinteraktioner, da Entresto kun i begrænset omfang metaboliseres via CYP-enzymer.
English: Because of the potential risk for adverse reactions in breast-fed newborns/infants, it is not recommended during breast-feeding.
Danish: På grund af den potentielle risiko for bivirkninger hos de ammede nyfødte/spædbørn, bør Entresto ikke anvendes under amning.
English: If patients experience tolerability issues (systolic blood pressure [SBP] ≤95 mmHg, symptomatic hypotension, hyperkalaemia, renal dysfunction), adjustment of concomitant medicinal products, temporary down-titration or discontinuation of Entresto is recommended (see section 4.4).
Danish: Hvis patienten oplever tolerabilitetsproblemer (systolisk blodtryk [SBT] ≤95 mmHg, symptomatisk hypotension, hyperkaliæmi, nedsat nyrefunktion), er justering af samtidigt administrerede lægemidler, midlertidig nedtitrering eller seponering af Entresto anbefalet (se pkt.
English: Sudden death accounted for 45% of cardiovascular deaths and was reduced by 20% in Entresto-treated patients compared to enalapril-treated patients (HR 0.80, p=0.0082).
Danish: Pludselig død udgjorde 45 % af de kardiovaskulære dødsfald og blev reduceret med 20 % hos Entrestobehandlede patienter sammenlignet med enalaprilbehandlede patienter (HR 0,80, p=0,0082).
English: Do not take Entresto with ACE inhibitors.
Danish: Tag ikke Entresto sammen med ACE-hæmmere.
English: Use of Entresto may be associated with an increased risk of hyperkalaemia, although hypokalaemia may also occur (see section 4.8).
Danish: Anvendelse af Entresto kan være forbundet med en øget risiko for hyperkaliæmi, selvom hypokaliæmi også kan forekomme (se pkt.
English: In PARADIGM-HF study, Entresto was administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other angiotensin II receptor blocker (ARB) (see section 5.1).
Danish: I PARADIGM-HF-studiet blev Entresto administreret sammen med anden medicin til hjertesvigt, enten i stedet for en ACE-hæmmer eller andre angiotensin-II-receptorblokkere (ARB) (se pkt.
English: Pump failure accounted for 26% of cardiovascular deaths and was reduced by 21% in Entresto-treated patients compared to enalapril-treated patients (HR 0.79, p=0.0338).
Danish: Pumpesvigt udgjorde 26 % af de kardiovaskulære dødsfald og blev reduceret med 21 % hos Entrestobehandlede patienter sammenlignet med enalaprilbehandlede patienter (HR 0,79, p=0,0338).
English: No clinically relevant drug-drug interaction was observed when simvastatin and Entresto were coadministered.
Danish: Der blev ikke observeret nogen klinisk relevant interaktion ved kombinationsbehandling med simvastatin og Entresto.
English: Therefore, monitoring of renal function is recommended when initiating or modifying treatment in patients on Entresto who are taking NSAIDs concomitantly (see section 4.4).
Danish: Det anbefales derfor at overvåge nyrefunktionen ved start eller ved ændring af behandlingen hos patienter, der får Entresto og samtidig tager NSAID (se pkt.
English: In the PARADIGM-HF study, subjects were previously treated with ACE inhibitors and/or ARBs and also had to successfully complete sequential enalapril and Entresto run-in periods (median drug exposure of 15 and 29 days, respectively) prior to the randomised double-blind period.
Danish: I PARADIGM-HF-studiet var patienterne tidligere behandlet med ACE-hæmmere og/eller ARB og skulle også inden den randomiserede dobbeltblindede periode fuldføre en sekventiel enalapril og Entresto run-in periode (gennemsnitlig lægemiddeleksponering var henholdsvis 15 og 29 dage).
English: The safety of Entresto in patients with chronic heart failure was evaluated in the pivotal phase 3 study PARADIGM-HF, which compared patients treated twice daily with Entresto 97 mg/103 mg (n=4,203) or enalapril 10 mg (n=4,229).
Danish: Sikkerheden af Entresto hos patienter med kronisk hjertesvigt blev undersøgt i det pivotale fase 3studie PARADIGM-HF, hvor man sammenlignede patienter behandlet 2 gange daglig med enten 97 mg/103 mg Entresto (n=4203) eller 10 mg enalapril (n=4229).
English: More patients who were naïve to previous ACE inhibitor or ARB therapy or on low-dose therapy (equivalent to <10 mg enalapril/day) were able to achieve and maintain Entresto 200 mg when up-titrated over 6 weeks (84.8%) versus 3 weeks (73.6%).
Danish: Flere patienter, som ikke tidligere havde været behandlet med ACE-hæmmer eller ARB, eller som var på lavdosisbehandling (svarende til <10 mg enalapril/dag), kunne opnå og vedligeholde 200 mg Entresto ved optitrering over 6 uger (84,8 %) versus 3 uger (73,6 %).
English: The components of Entresto, sacubitril and valsartan, were excreted in the milk of lactating rats (see section 5.3).
Danish: Entrestos komponenter sacubitril og valsartan blev udskilt i mælk hos diegivende rotter (se pkt.
English: In the PARADIGM-HF study, Entresto decreased plasma NT-proBNP and increased plasma BNP and urine cGMP compared with enalapril.
Danish: I PARADIGM-HF-studiet mindskede Entresto plasma NTproBNP og øgede plasma BNP og urin cGMP sammenlignet med enalapril.
English: Talk to your doctor, pharmacist or nurse before taking Entresto
Danish: Kontakt lægen, apotekspersonalet eller sygeplejersken før du tager Entresto:
English: The effects of Entresto on amyloid-β concentrations in CSF and brain tissue were assessed in young (2-4 years old) cynomolgus monkeys treated with Entresto (24 mg sacubitril/26 mg valsartan/kg/day) for two weeks.
Danish: Entrestos virkning på koncentrationen af amyloid-β i CSF og hjernevæv blev undersøgt hos unge (2-4 år gamle) cynomolgus aber behandlet med Entresto (24 mg sacubitril/26 mg valsartan/kg/dag) i to uger.
English: During the Entresto run-in period, 10.4% of patients permanently discontinued, 5.9% because of an adverse reaction, most commonly renal dysfunction (1.8%), hypotension (1.7%) and hyperkalemia (1.3%).
Danish: Under Entresto run-in perioden udgik 10,4 % af patienterne permanent, 5,9 % på grund af en bivirkning, hyppigst renal dysfunktion (1,8 %), hypotension (1,7 %) og hyperkaliæmi (1,3 %).
English: It must not be re-administered.
Danish: Entresto må ikke gives igen.
English: Based on the comparison of plasma and CSF exposures, LBQ657 crosses the blood brain barrier to a limited extent
Danish: Vurderet ud fra sammenligning af plasma- og CSF-koncentrationer passerer LBQ657 blodhjernebarrieren i begrænset omfang (0,28 %).
English: • other medicines used to treat heart failure or lower blood pressure, such as angiotensin receptor blockers or aliskiren (see “Do not take Entresto”).
Danish: • anden medicin brugt til at behandle hjertesvigt eller til at sænke blodtrykket, som fx angiotensin-receptorblokker eller aliskiren (se ”Tag ikke Entresto”).
English: Entresto contains valsartan, and therefore should not be co-administered with another ARB containing product (see section 4.4).
Danish: Da Entresto indeholder valsartan, bør det ikke anvendes sammen med et andet produkt indeholdende en ARB (se pkt 4.4).
English: Co-administration of Entresto increased the Cmax of atorvastatin and its metabolites by up to 2-fold and AUC by up to 1.3-fold.
Danish: Anvendelse sammen med Entresto øgede Cmax af atorvastatin og dets metabolitter op til 2 gange og AUC op til 1,3 gange.
English: The valsartan contained within Entresto is more bioavailable than the valsartan in other marketed tablet formulations (see section 5.2).
Danish: Biotilgængeligheden af valsartan-komponenten i Entresto er højere end biotilgængeligheden af valsartan i andre markedsførte tabletformuleringer (se pkt.
English: Entresto should not be co-administered with an ACE inhibitor or an ARB. Due to the potential risk of angioedema when used concomitantly with an ACE inhibitor, it must not be started for at least 36 hours after discontinuing ACE inhibitor therapy (see sections 4.3, 4.4 and 4.5).
Danish: Entresto må ikke administreres sammen med en ACE-hæmmer eller en ARB. På grund af mulig risiko for angioødem, må behandling med Entresto ikke startes før mindst 36 timer efter, at behandling med en ACE-hæmmer er afbrudt (se pkt.
English: • if you have diabetes or impaired kidney function and you are being treated with a blood pressure lowering medicine containing aliskiren (see “Other medicines and Entresto”).
Danish: • hvis du har sukkersyge eller nedsat nyrefunktion, og du bliver behandlet med et blodtrykssænkende lægemiddel, der indeholder aliskiren (se ”Brug af anden medicin sammen med Entresto”).
English: What Entresto contains
Danish: Entresto indeholder:
English: The pharmacokinetics of Entresto (sacubitril, LBQ657 and valsartan) are similar between male and female subjects.
Danish: Køn Entrestos (sacubitril, LBQ657 og valsartan) farmakokinetik er den samme hos mænd og kvinder.
English: • if you are being treated with an angiotensin receptor blocker (ARB) or aliskiren (see “Do not take Entresto”).
Danish: • hvis du bliver behandlet med en angiotensin-receptorblokker (ARB) eller aliskiren (se ”Tag ikke
English: A single dose of Entresto 583 mg sacubitril/617 mg valsartan and multiple doses of 437 mg sacubitril/463 mg valsartan (14 days) were studied in healthy volunteers and were well tolerated.
Danish: En enkelt dosis Entresto på 583 mg sacubitril/617 mg valsartan og gentagne doser på 437 mg sacubitril/463 mg valsartan (14 dage) blev undersøgt hos voksne frivillige forsøgspersoner og var veltolererede.
English: Entresto may be administered with or without food (see section 5.2).
Danish: Entresto kan indtages med eller uden mad (se pkt.
English: In elderly patients, volume-depleted patients (including those on diuretic therapy), or patients with compromised renal function, concomitant use of Entresto and NSAIDs may lead to an increased risk of worsening of renal function.
Danish: Anvendelse af Entresto sammen med NSAIDer kan hos ældre patienter, patienter med væskemangel (inklusive dem som er i diuretisk behandling) eller patienter med kompromitteret nyrefunktion medføre øget risiko for forværring af nyrefunktionen.
English: If any of the above applies to you, do not take Entresto and talk to your doctor.
Danish: Hvis noget af ovenstående passer på dig, må du ikke tage Entresto, før du har talt med din læge.
English: In the Entresto group, 76% of patients remained on the target dose of 200 mg twice daily at the end of the study (mean daily dose of 375 mg).
Danish: I Entrestogruppen var 76 % af patienterne stadigvæk på måldosis 200 mg 2 gange daglig ved afslutningen af forsøget (gennemsnitlig daglig dosis på 375 mg).
English: Pre- and postnatal development studies in rats conducted with sacubitril at high doses up to 750 mg/kg/day (2.2-fold the MRHD on the basis of AUC) and valsartan at doses up to 600 mg/kg/day (0.86-fold the MRHD on the basis of AUC) indicate that treatment with Entresto during organogenesis, gestation and lactation may affect pup development and survival.
Danish: Pre- og postnatale udviklingsstudier hos rotter udført med sacubitril i høje doser, op til 750 mg/kg/dag (2,2 gange MRHD vurderet ud fra AUC) og valsartan i doser op til 600 mg/kg/dag (0,86 gange MRHD vurderet ud fra AUC), tyder på, at behandling med Entresto under organdannelse, gestation og laktation kan påvirke ungernes udvikling og overlevelse.
English: The tablets are supplied in PVC/PVDC/Aluminium blister packs of 14, 20, 28, 56, 168 or 196 tablets and in multipacks of 196 tablets (7 packs of 28 tablets).
Danish: Tabletterne leveres i PVC/PVDC/Aluminiumsblisterpakninger med 14, 20, 28, 56, 168 eller 196 tabletter og i multipakninger med 196 tabletter (7 pakninger med 28 tabletter).
English: Other medicines and Entresto Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.
Danish: Brug af anden medicin sammen med Entresto Fortæl altid lægen, apotekspersonalet eller sygeplejersken, hvis du bruger anden medicin eller har gjort det for nylig.
English: Co-administration of nitroglycerin and Entresto was associated with a treatment difference of 5 bpm in heart rate compared to the administration of nitroglycerine alone.
Danish: Samtidig indgift af nitroglycerin og Entresto var ledsaget af en behandlingsforskel i hjertefrekvensen på 5 slag/minut sammenlignet med indgift af nitroglycerin alene.
English: In a 21-day study in HFrEF patients, Entresto significantly increased urine ANP and cGMP and plasma cGMP, and decreased plasma NT-proBNP, aldosterone and endothelin-1 compared to baseline.
Danish: I et 21-dages studie hos HFrEF-patienter øgede Entresto urin ANP og cGMP, og plasma cGMP, og mindskede plasma NT-proBNP, aldosteron og endothelin-1 sammenlignet med baseline.
English: No dose adjustment is required when administering Entresto to patients with mild hepatic impairment (Child-Pugh A classification).
Danish: Dosisjustering er ikke påkrævet, når Entresto gives til patienter med let nedsat leverfunktion (ChildPugh klasse A).
English: Angioedema has been reported in patients treated with Entresto.
Danish: Der er forekommet angioødem hos patienter behandlet med Entresto.
English: In PARADIGM-HF, hypotension and clinically relevant low systolic blood pressure (<90 mmHg and decrease from baseline of >20 mmHg) were reported in 17.6% and 4.76% of Entresto-treated patients compared with 11.9% and 2.67% of enalapril-treated patients, respectively.
Danish: I PARADIGM-HF forekom hypotension og klinisk relevant lavt systolisk blodtryk (<90 mmHg og reduktion fra baseline på >20 mmHg) hos henholdsvis 17,6 % og 4,76 % af patienter behandlet med Entresto sammenlignet med henholdsvis 11,9 % og 2,67 % af patienter behandlet med enalapril.
English: Overall, 76% of patients achieved and maintained the target dose of Entresto 200 mg twice daily without any dose interruption or down-titration over 12 weeks.
Danish: Samlet nåede 76 % af patienterne op på Entrestos måldosis 200 mg to gange daglig og kunne vedligeholde den uden afbrydelse eller nedtitrering i studieperioden på 12 uger.
English: In a 7-day valsartan-controlled study in patients with reduced ejection fraction (HFrEF), administration of Entresto resulted in an initial increase in natriuresis, increased urine cGMP, and decreased plasma levels of mid-regional pro-atrial natriuretic peptide (MR-proANP) and N-terminal prohormone brain natriuretic peptide (NT-proBNP) compared to valsartan.
Danish: I et 7-dages valsartankontrolleret studie hos patienter med nedsat uddrivningsfraktion (HFrEF), resulterede administration af Entresto i en initial øgning i natriurese, øget urin cGMP og sænkede plasmakoncentrationer af MR-proANP (mid-regional proatrial natriuretic peptide) og NT-proBNP (N-terminal prohormone brain natriuretic peptide)
English: Entresto does not induce or inhibit CYP450 enzymes.
Danish: Entresto hverken inducerer eller hæmmer CYP-enzymer.
English: The adverse embryofoetal effects of Entresto are attributed to the angiotensin receptor antagonist activity (see section 4.6).
Danish: De negative embryoføtale virkninger af Entresto er relateret til angiotensin-receptor-antagonistvirkningen (se pkt.
English: In a thorough QTc clinical study in healthy male subjects, single doses of Entresto 194 mg sacubitril/206 mg valsartan and 583 mg sacubitril/617 mg valsartan had no effect on cardiac repolarisation.
Danish: I et omhyggeligt QTc-studie hos raske, frivillige mænd havde enkeltdoser på Entresto 194 mg sacubitril/206 mg valsartan og 583 mg sacubitril/617 mg valsartan ingen virkning på hjertets repolarisation.
English: Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1).
Danish: Entresto er indiceret til behandling af voksne patienter med symptomatisk kronisk hjertesvigt med nedsat uddrivningsfraktion (se pkt.
English: Monitoring of serum potassium is recommended if Entresto is co-administered with these agents (see section 4.4).
Danish: Det anbefales at monitorere serumkalium, hvis Entresto administreres sammen med disse stoffer (se pkt.
English: The complementary cardiovascular benefits of Entresto in heart failure patients are attributed to the enhancement of peptides that are degraded by neprilysin, such as natriuretic peptides (NP), by LBQ657 and the simultaneous inhibition of the effects of angiotensin II by valsartan.
Danish: Entrestos komplementære kardiovaskulære fordele hos patienter med hjertesvigt forklares med, at peptider, som nedbrydes af neprilysin, som fx natriuretiske peptider (NP), øges ved hjælp af LBQ657 samtidigt med, at de virkninger, som forårsages af angiotensin II, hæmmes ved hjælp af valsartan.
English: Discontinuation of therapy due to an adverse reaction in the double-blind period of the PARADIGM-HF study occurred in 450 Entresto-treated patients (10.7%) and 516 enalapril-treated patients (12.2%).
Danish: I den dobbeltblinde periode af PARADIGM-HF-studiet forekom afbrydelse af behandlingen hos 450 patienter behandlet med Entresto (10,7 %) og 516 patienter behandlet med enalapril (12,2 %).
English: It is advisable to take your medicine at the same time each day.
Danish: Hvis du har glemt at tage Entresto Det anbefales, at tage medicinen på samme tidspunkt hver dag.
English: No. at risk Entresto
Danish: Antal risikopatienter Entresto
English: In PARADIGM-HF, hyperkalaemia and serum potassium concentrations >5.4 mmol/l were reported in 11.6% and 19.7% of Entresto-treated patients and 14.0% and 21.1% of enalapril-treated patients, respectively.
Danish: I PARADIGM-HF forekom hyperkaliæmi og serumkaliumkoncentrationer på >5,4 mmol/l hos henholdsvis 11,6 % og 19,7 % af patienter behandlet med Entresto og henholdsvis 14,0 % og 21,1 % af patienter behandlet med enalapril.
English: The most commonly reported adverse reactions during treatment with Entresto were hypotension, hyperkalaemia and renal impairment (see section 4.4).
Danish: De mest almindeligt rapporterede bivirkninger ved behandling med Entresto var hypotension, hyperkaliæmi og nedsat nyrefunktion (se pkt.
English: ***One-sided p-value ♯ Full analysis set
Danish: ***En-sidet p-værdi
English: Entresto should be used with caution in these patients and the recommended starting dose is 24 mg/26 mg twice daily (see sections 4.4 and 5.2).
Danish: Entresto skal derfor anvendes med forsigtighed hos disse patienter og den anbefalede startdosis er 24 mg/26 mg to gange daglig (se pkt.
English: In this study CSF Aβ clearance in cynomolgus monkeys was reduced, increasing CSF Aβ1-40, 1-42 and 1-38 levels; there was no corresponding increase in Aβ levels in the brain.
Danish: I dette studie var CSF Aβ clearence hos cynomolgus aber reduceret, idet CSF Aβ1-40, 1-42 og 138 niveauer øgedes.
English: Entresto is contraindicated in patients with a known history of angioedema related to previous ACE inhibitor or ARB therapy or with hereditary or idiopathic angioedema (see section 4.3).
Danish: Entresto er kontraindiceret hos patienter, som tidligere har oplevet angioødem relateret til ACE-hæmmere, til behandling med ARB eller med hereditær eller idiopatisk angioødem (se pkt.
English: Animal studies with Entresto have shown reproductive toxicity (see section 5.3).
Danish: Dyrestuder med Entresto har vist reproduktionstoksicitet (se pkt.
English: Interactions between Entresto and lithium have not been investigated.
Danish: Interaktion mellem Entresto og lithium er ikke undersøgt, denne kombination kan derfor ikke anbefales.
English: Patients were required to discontinue their existing ACE inhibitor or ARB therapy and enter a sequential single-blind run-in period during which they received treatment with enalapril 10 mg twice daily, followed by single-blind treatment with Entresto 100 mg twice daily, increasing to 200 mg twice daily (see section 4.8 for discontinuations during this period).
Danish: Patienterne skulle afbryde deres eksisterende ACE-hæmmer- eller ARB-behandling og indgå i en sekventiel enkeltblindet run-in periode, i hvilken de blev behandlet med 10 mg enalapril 2 gange daglig efterfulgt af enkeltblindet behandling med Entresto 100 mg 2 gange daglig stigende til 200 mg 2 gange daglig (se pkt.
English: Combination of Entresto with aliskiren is potentially associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) (see sections 4.3 and 4.4).
Danish: Kombination af Entresto med aliskiren er muligvis forbundet med en højere hyppighed af bivirkniner som fx hypotension, hyperkaliæmi og nedsat nyrefunktion (inklusive akut nyresvigt) (se pkt.
English: BNP is not a suitable biomarker of heart failure in patients treated with Entresto because BNP is a neprilysin substrate (see section 4.4).
Danish: BNP er ikke egnet som biomarkør for hjertesvigt hos patienter i behandling med Entresto, da BNP er et neprilysinsubstrat (se pkt.
English: The pharmacokinetics of sacubitril, LBQ657 and valsartan were approximately linear over an Entresto dose range of 24 mg sacubitril/26 mg valsartan to 97 mg sacubitril/103 mg valsartan.
Danish: Der er nogenlunde lineær farmakokinetik af sacubitril, LBQ657 og valsartan i et dosisinterval af Entresto mellem 24 mg sacubitril/26 mg valsartan og 97 mg sacubitril/103 mg valsartan.
English: BNP is not a suitable biomarker of heart failure in patients treated with Entresto because it is a neprilysin substrate (see section 5.1).
Danish: BNP er ikke egnet som markør for hjertesvigt hos patienter behandlet med Entresto, da dette er et neprilysinsubstrat (se pkt.
English: If you stop taking Entresto, wait 36 hours after taking your last dose of Entresto before starting an ACE inhibitor.
Danish: Hvis du stopper med at tage Entresto, skal du vente i 36 timer efter at have taget din sidste dosis Entresto, før du må begynde at tage en ACE-hæmmer.
English: In PARADIGM-HF, renal impairment was reported in 10.1% of Entresto-treated patients and 11.5% of enalapril-treated patients.
Danish: I PARADIGM-HF forekom nedsat nyrefunktion hos 10,1 % af patienter behandlet med Entresto og hos 11,5 % af patienter behandlet med enalapril.
English: Entresto exhibits the mechanism of action of an angiotensin receptor neprilysin inhibitor by simultaneously inhibiting neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and by blocking the angiotensin II type-1 (AT1) receptor via valsartan.
Danish: Entresto udøver virkningsmekanismen af en angiotensinreceptor-neprilysin-hæmmer idet LBQ657, som er den aktive metabolit af prodruget sacubitril, hæmmer neprilysin (neutral endopeptidase; NEP) samtidig med, at valsartan blokerer angiotensin II type-1 (AT1) receptoren.
English: There are no available data on the effect of Entresto on human fertility.
Danish: Virkningen af Entresto på human fertilitet er ikke undersøgt.
English: 14 film-coated tablets 20 film-coated tablets 28 film-coated tablets 56 film-coated tablets 168 film-coated tablets 196 film-coated tablets
Danish: 14 filmovertrukne tabletter 20 filmovertrukne tabletter 28 filmovertrukne tabletter 56 filmovertrukne tabletter 168 filmovertrukne tabletter 196 filmovertrukne tabletter
English: If any of the above applies to you, tell your doctor, pharmacist or nurse before you take Entresto.
Danish: Hvis noget af ovenstående passer på dig, skal du tale med din læge, apotekspersonalet eller sygeplejersken, før du tager Entresto.